Palisade Bio
PALI
5 hedge funds and large institutions have $359K invested in Palisade Bio in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
44% less capital invested
Capital invested by funds: $644K → $359K (-$285K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$108K |
| 2 |
Bank of New York Mellon
New York
|
+$47.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$255K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3K |
PALI Hedge Fund Activity: Q1 2020 in Review
5 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2020, worth a combined $359K — down 44% from $644K a quarter earlier.
Fund positioning in PALI was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $108K. The largest seller was Sabby Management, cutting an estimated $255K.
- 5 institutional investors held Palisade Bio (PALI) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $359K of Palisade Bio stock for Q1 2020, down 44% quarter-over-quarter.
- 1 fund opened new Palisade Bio positions in Q1 2020 and 1 closed out, a net change of 0 holders.
- The largest Palisade Bio buyer in Q1 2020 was Renaissance Technologies, an estimated $108K added.
- The largest Palisade Bio seller in Q1 2020 was Sabby Management, an estimated $255K sold.
Based on aggregated 13F filings for Q1 2020.